Please try another search
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw materials, and cosmetics. The company was formerly known as Bioleaders Corporation and changed its name to MOA Life Plus Co. Ltd. in March 2024. MOA Life Plus Co. Ltd. was founded in 1999 and is headquartered in Yongin-Si, South Korea.
Name | Age | Since | Title |
---|---|---|---|
In-Sik Park | 55 | - | External Director |
Seung-Pyo Hong | 59 | - | Director |
Chang-Kyun Kim | 68 | - | Vice Chairman |
Park Young Chul | - | - | CEO & Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review